Chapter 27: Antidysrhythmic Drugs – Cardiac Rhythm Control

Antidysrhythmic Drugs – Cardiac Rhythm Control begins by establishing the fundamentals of cardiac electrophysiology, reviewing the anatomy and function of the conduction system, and detailing the action potential—the electrical cycle defined by phases 0 through 4—which involves the precise movement of ions such as sodium, potassium, and calcium across the cell membrane, resulting in depolarization and repolarization. Disturbances in automaticity, or the spontaneous depolarization of pacemaker cells (like the SA node, AV node, and His-Purkinje fibers), lead to various dysrhythmias, ranging from common conditions like atrial fibrillation (which significantly increases stroke risk) to life-threatening ventricular rhythms such as sustained ventricular tachycardia and torsades de pointes. Antidysrhythmic agents are categorized primarily by the Vaughan Williams classification system (Classes I through IV), based on their specific mechanism of action on the cardiac action potential. Class I drugs (e.g., lidocaine, flecainide) are fast sodium channel blockers, subdivided by their effects on repolarization. Class II agents are beta blockers that reduce sympathetic stimulation and depress phase 4 depolarization. Class III drugs (e.g., amiodarone, sotalol) prolong repolarization and the action potential duration, often reserved for difficult-to-treat dysrhythmias. Class IV agents (e.g., verapamil, diltiazem) are calcium channel blockers that slow conduction in the SA and AV nodes. A major consideration for these medications is their potential to worsen or cause new dysrhythmias (prodysrhythmic effects), often associated with QT interval prolongation. Key high-alert drugs, particularly amiodarone, require intensive monitoring due to severe adverse effects like pulmonary toxicity and significant drug interactions, especially with warfarin and digoxin. The nursing process involves careful assessment of baseline cardiac status, vigilant monitoring of vital signs and ECG tracings during initiation of therapy, and thorough patient education regarding contraindications, adverse effects (such as cinchonism or photosensitivity), and the necessity of avoiding interacting substances like grapefruit juice.